Anti-neoplastic effects of fucoxanthin and its deacetylated product, fucoxanthinol, on Burkitt's and Hodgkin's lymphoma cells

Tafuku,Senji; Ishikawa,Chie; Yasumoto,Takeshi; Mori,Naoki

doi:10.3892/or.2012.1947

Anti-neoplastic effects of fucoxanthin and its deacetylated product, fucoxanthinol, on Burkitt's and Hodgkin's lymphoma cells

Authors:
- Senji Tafuku
- Chie Ishikawa
- Takeshi Yasumoto
- Naoki Mori
View Affiliations

Affiliations: Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan, Marine Bio Industry Division, Okinawa Science and Technology Promotion Center, Naha, Okinawa 900-0029, Japan
Published online on: August 3, 2012 https://doi.org/10.3892/or.2012.1947
Pages: 1512-1518

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fucoxanthin (FX) is a natural carotenoid with reported antitumorigenic activity. This study explored the effects of FX and its deacetylated product, fucoxanthinol (FXOH), on B-cell malignancies, including Burkitt's lymphoma, Hodgkin's lymphoma and Epstein-Barr virus-immortalized B cells. Both FX and FXOH reduced the viability of these malignant B cells in a dose-dependent manner accompanied by the induction of cell cycle arrest during G1 phase and caspase-dependent apoptosis. FXOH was approximately twice more potent than FX in these activities. In contrast, normal peripheral blood mononuclear cells were resistant to FX and FXOH. Strong and constitutive activation of nuclear factor-κB (NF-κB) is a common characteristic of many B-cell malignancies, and FXOH suppressed constitutive NF-κB activity. NF-κB inhibition was accompanied by downregulation of NF-κB-dependent anti-apoptotic and cell cycle regulator gene products, including Bcl-2, cIAP-2, XIAP, cyclin D1 and cyclin D2. The results indicated that FX and FXOH are potentially useful therapeutic agents in B-cell malignancies characterized by aberrant regulation of NF-κB.

View Figures

View References

1	Epstein MA, Achong BG and Barr YM: Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1:702–703. 1964.PubMed/NCBI
2	Taylor GS and Blackbourn DJ: Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV. Cancer Lett. 305:263–278. 2011. View Article : Google Scholar : PubMed/NCBI
3	Mounier N, Spina M and Gisselbrecht C: Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol. 136:685–698. 2007. View Article : Google Scholar : PubMed/NCBI
4	Re D, Thomas RK, Behringer K and Diehl V: From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. 105:4553–4560. 2005. View Article : Google Scholar : PubMed/NCBI
5	Chaturvedi MM, Sung B, Yadav VR, Kannappan R and Aggarwal BB: NF-κB addiction and its role in cancer: ‘one size does not fit all’. Oncogene. 30:1615–1630. 2011.
6	Liebowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 338:1413–1421. 1998. View Article : Google Scholar : PubMed/NCBI
7	Peng J, Yuan J-P, Wu C-F and Wang J-H: Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs. 9:1806–1828. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kim K-N, Heo S-J, Yoon W-J, Kang S-M, Ahn G, Yi T-H and Jeon Y-J: Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol. 649:369–375. 2010.PubMed/NCBI
9	Zhang C, Ao Z, Seth A and Schlossman SF: A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol. 157:3980–3987. 1996.PubMed/NCBI
10	Antalis TM and Godbolt D: Isolation of intact nuclei from hematopoietic cell types. Nucleic Acids Res. 19:43011991. View Article : Google Scholar : PubMed/NCBI
11	Vallabhapurapu S and Karin M: Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol. 27:693–733. 2009.
12	Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 18:6853–6866. 1999.
13	Grossmann M, O’Reilly LA, Gugasyan R, Strasser A, Adams JM and Gerondakis S: The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J. 19:6351–6360. 2000. View Article : Google Scholar : PubMed/NCBI
14	Wäldele K, Silbermann K, Schneider G, Ruckes T, Cullen BR and Grassmann R: Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Blood. 107:4491–4499. 2006.PubMed/NCBI
15	Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR and Lipp J: Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J Exp Med. 188:211–216. 1998.
16	Iwanaga R, Ohtani K, Hayashi T and Nakamura M: Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene. 20:2055–2067. 2001. View Article : Google Scholar
17	Huang Y, Ohtani K, Iwanaga R, Matsumura Y and Nakamura M: Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene. 20:1094–1102. 2001. View Article : Google Scholar : PubMed/NCBI
18	Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C and Strauss M: NF-κB function in growth control: regulation of cyclin D1 expression and G₀/G₁-to-S-phase transition. Mol Cell Biol. 19:2690–2698. 1999.
19	Jost PJ and Ruland J: Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 109:2700–2707. 2007.
20	Kimura N, Miyakawa Y, Kohmura K, Umezawa K, Ikeda Y and Kizaki M: Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. Leuk Res. 31:1529–1535. 2007.
21	Küppers R: Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 491–496. 2009.
22	Sugawara T, Baskaran V, Tsuzuki W and Nagao A: Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J Nutr. 132:946–951. 2002.PubMed/NCBI
23	Asai A, Yonekura L and Nagao A: Low bioavailability of dietary epoxyxanthophylls in humans. Br J Nutr. 100:273–277. 2008. View Article : Google Scholar : PubMed/NCBI
24	Sherr CJ and Roberts JM: Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
25	Burstein E and Duckett CS: Dying for NF-κB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol. 15:732–737. 2003.